Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neurex/Warner-Lambert SNX-111 head injury pivotal trial resumes, with target completion date in two years.

Executive Summary

NEUREX SNX-111 HEAD TRAUMA TRIAL SCHEDULED FOR COMPLETION IN TWO YEARS, the Menlo Park, Calif.- based company said following the Sept. 3 resumption of the 800-patient Phase III trial being conducted by marketing partner Warner-Lambert. The trial was suspended in July with very few patients enrolled after an analysis of Phase I/II studies found a "disparity" between the drug and placebo groups ("The Pink Sheet" Aug. 4, T&G-8).



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts